Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Sneksy/E+ via Getty Images Introduction I last wrote on Verona Pharma plc (NASDAQ:VRNA) a year ago. My recommendation was "buy," noting the potential of their novel COPD treatment. Since then, its selective dual phosphodiesterase-3 (PDE3) and phosphodiesterase-4 (PDE4) inhibitor, Ohtuvayre (ensifentrine), was approved for the treatment of COPD. Subsequently, its stock has appreciated over 50% during this time. So I figure it's a good time to take another look at Verona as they begin launching Ohtuvayre. Ver ...